HBV risk · 3 minutes

Hepatitis B risk screener

Eight questions about exposure history, family origin, and clinical risk factors. Result tells you whether HBV testing is recommended — and what evaluation looks like at a Class A hepatology department in China.

← All self-assessments

1 of 80% complete
Question 1

Were you, or either of your parents, born in a country with intermediate or high HBV prevalence?

Includes China, Vietnam, Korea, Philippines, Indonesia, sub-Saharan Africa, Middle East, Eastern Europe.

Educational tool — not a diagnosis. Risk-factor screener aligned with US CDC and AASLD HBV testing recommendations and the 2023 China HBV management guideline. Educational only — diagnosis requires serology.

Frequently asked

Plain-language answers about hepatitis b risk, this screener, and what evaluation costs at a Class A hospital in China.

Should I get tested for hepatitis B?
Most international guidelines recommend at least one-time HBV testing for adults. Higher-risk groups (people born in HBV-endemic regions including China and SE Asia, family history of HBV, IV drug use, multiple sexual partners) should be tested without delay.
What does HBV testing cost in China?
The standard panel (HBsAg + anti-HBs + anti-HBc) is $15–30 at any Class A international department. Adding HBV DNA quantitation, FibroScan, and a hepatology consult is typically $80–150 all-in.
What's the cost of tenofovir antiviral treatment in China?
Generic tenofovir disoproxil (TDF) is $5–15/month. Tenofovir alafenamide (TAF, Vemlidy) is $15–30/month — vs $1,200–1,800/month in the US for the same drug. See our Tenofovir-Hepatitis-B page.

About this screener

Risk-factor screener aligned with US CDC and AASLD HBV testing recommendations and the 2023 China HBV management guideline. Educational only — diagnosis requires serology.

What this screener covers

  • Chronic hepatitis B(ICD-10 B18.1)
  • Hepatocellular carcinoma surveillance(ICD-10 Z08.7)

Medical review

Reviewed by Panda Touring Care medical team (Hepatology coordinator review) · last reviewed 2025-04-01